WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Dicerna), a RNA interference (RNAi) company focused on developing breakthrough oncology therapeutics, today announced that results from the company’s hepatocellular cancer (HCC) program were presented at the International Liver Cancer Association (ILCA) Annual Conference held in Berlin, September 14 – 16, 2012. The data were featured in three separate poster presentations at the meeting. Dicerna has developed a growing pipeline of Dicer Substrate siRNA (DsiRNA) molecules and related drug delivery technologies, including its EnCore™ lipid nanoparticle technology, using its Dicer Substrate Technology™ platform.
